project . 2015 - 2020 . Closed

ApoptoMDS

Hematopoietic stem cell Apoptosis in bone marrow failure and MyeloDysplastic Syndromes: Friend or foe?
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 638145 Call for proposal: ERC-2014-STG
  • Funded under: H2020 | ERC | ERC-STG Overall Budget: 1,372,520 EURFunder Contribution: 1,372,520 EUR
  • Status: Closed
  • Start Date
    01 Jun 2015
    End Date
    31 May 2020
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Deregulated apoptotic signaling in hematopoietic stem and progenitor cells (HSPCs) strongly contributes to the pathogenesis and phenotypes of congenital bone marrow failure and myelodysplastic syndromes (MDS) and their progression to acute myeloid leukemia (AML). HSPCs are highly susceptible to apoptosis during bone marrow failure and early MDS, but AML evolution selects for apoptosis resistance. Little is known about the main apoptotic players and their regulators. ApoptoMDS will investigate the impact of apoptotic deregulation for pathogenesis, correlate apoptotic susceptibility with the kinetics of disease progression and characterize the mechanism by which a...
Description
Deregulated apoptotic signaling in hematopoietic stem and progenitor cells (HSPCs) strongly contributes to the pathogenesis and phenotypes of congenital bone marrow failure and myelodysplastic syndromes (MDS) and their progression to acute myeloid leukemia (AML). HSPCs are highly susceptible to apoptosis during bone marrow failure and early MDS, but AML evolution selects for apoptosis resistance. Little is known about the main apoptotic players and their regulators. ApoptoMDS will investigate the impact of apoptotic deregulation for pathogenesis, correlate apoptotic susceptibility with the kinetics of disease progression and characterize the mechanism by which a...
Any information missing or wrong?Report an Issue